E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
patients after successful cardioversion of atrial fibrillation |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate the effects of statin treatment on (hs)-CRP-levels |
|
E.2.2 | Secondary objectives of the trial |
To investigate the effects of statin treatment on the following: -Recurrence rate and time to recurrence of AF -Established risk markers including lipid subfractions and other biomarkers of cardiovascular risk in AF (such as von Willebrand factor, adhesion molecules, etc.) |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
-Age>18yrs -At least second episode of non valvular, persistent, symptomatic AF within one year, defined by an echocardiogram asserting non valvular origin and a duration of at least 12 hours. -Patient willing to undergo cardioversion if no spontaneous conversion to sinus rhythm occurs within 12 hours -Written informed consent
|
|
E.4 | Principal exclusion criteria |
-First episode of AF -Last episode longer than a year ago
-Termination within 12 hours -Transient atrial fibrillation caused by known reversible disorders (thyrotoxicosis, alcohol intoxication etc.) -Known refractoriness to cardioversion (after several trials, permanent AF) -Severe valvular heart disease -Current atrial myxoma or left ventricular thrombus -Left Ventricular Ejection Fraction < 30% -Severe rhythmological disorders other than AF (WPW-Syndrome, AV block II-III etc) - Prolonged QT interval (QTc interval of >500ms) -Stroke within the previous 30 days or transient ischaemic attack within 3 days -Treatment with fibrinolytic agents within 30 days before randomisation -History of intracranial, intraocular, spinal, retroperitoneal, overt gastrointestinal or atraumatic intra-articular bleeding during the last year -Endoscopically verified ulcer disease in the previous 30 days -Major surgical procedure or trauma in the previous 30 days -Planned major surgery -Haemorrhagic disorder -Admission for acute coronary syndrome or percutaneous coronary intervention within 30 days -Persistent blood pressure 180/100 mm Hg or greater with or without antihypertensive treatment -Need for regular use of non-steroidal anti-inflammatory at anti-inflammatory doses -Renal insufficiency (calculated creatinine clearance <30 mL/min) -Creatinine level of more than 2.5 mg per deciliter -Known severe hepatic disorders or persistent elevation of liver enzymes of more than two times the upper limit of normal -Unexplained elevation in the creatine kinase level more than three times the upper limit of normal -Women with child bearing potential -Drug addiction, alcohol abuse -Anaemia (haemoglobin <100 g/L or platelet count <100x109/L) -Abnormal electrolytes despite adequate therapy (especially potassium <3.5 or >5 mmol/L) -Estimated life expectancy <2 years -Already receiving statin therapy and need for statin therapy -Explicit need for statin therapy: Persons with established CHD or CHD risk equivalent (i.e. PAD or diabetes mellitus), who have a baseline LDL cholesterol ≥130 mg/dL -Known hypersensitivity to statins -Lipid-lowering therapy with fibric acid derivatives or niacin that cannot be discontinued before randomization, -Drugs that are strong inhibitors of cytochrome P-450 3A4 within the month before randomization or patients likely to require such treatment during the study period (because simvastatin is metabolized by this pathway)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |